HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays.
<h4>Background</h4>Several serological assays have been developed to detect antibodies elicited against infections with oncogenic human papillomavirus (HPV) type 16. The association between antibody levels measured by various assays and subsequent HPV infection risk may differ. We compar...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0053067&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850214883462742016 |
|---|---|
| author | Shih-Wen Lin Arpita Ghosh Carolina Porras Sarah C Markt Ana Cecilia Rodriguez Mark Schiffman Sholom Wacholder Troy J Kemp Ligia A Pinto Paula Gonzalez Nicolas Wentzensen Mark T Esser Katie Matys Ariane Meuree Wim Quint Leen-Jan van Doorn Rolando Herrero Allan Hildesheim Mahboobeh Safaeian Costa Rican Vaccine Trial Group |
| author_facet | Shih-Wen Lin Arpita Ghosh Carolina Porras Sarah C Markt Ana Cecilia Rodriguez Mark Schiffman Sholom Wacholder Troy J Kemp Ligia A Pinto Paula Gonzalez Nicolas Wentzensen Mark T Esser Katie Matys Ariane Meuree Wim Quint Leen-Jan van Doorn Rolando Herrero Allan Hildesheim Mahboobeh Safaeian Costa Rican Vaccine Trial Group |
| author_sort | Shih-Wen Lin |
| collection | DOAJ |
| description | <h4>Background</h4>Several serological assays have been developed to detect antibodies elicited against infections with oncogenic human papillomavirus (HPV) type 16. The association between antibody levels measured by various assays and subsequent HPV infection risk may differ. We compared HPV16-specific antibody levels previously measured by a virus-like particle (VLP)-based direct enzyme-linked immunoassay (ELISA) with levels measured by additional assays and evaluated the protection against HPV16 infection conferred at different levels of the assays.<h4>Methodology/principal findings</h4>Replicate enrollment serum aliquots from 388 unvaccinated women in the control arm of the Costa Rica HPV vaccine trial were measured for HPV16 seropositivity using three serological assays: a VLP-based direct ELISA; a VLP-based competitive Luminex immunoassay (cLIA); and a secreted alkaline phosphatase protein neutralization assay (SEAP-NA). We assessed the association of assay seropositivity and risk of subsequent HPV16 infection over four years of follow-up by calculating sampling-adjusted odds ratios (OR) and HPV16 seropositivity based on standard cutoff from the cLIA was significantly associated with protection from subsequent HPV16 infection (OR = 0.48, CI = 0.27-0.86, compared with seronegatives). Compared with seronegatives, the highest seropositive tertile antibody levels from the direct ELISA (OR = 0.53, CI = 0.28-0.90) as well as the SEAP-NA (OR = 0.20, CI = 0.06, 0.64) were also significantly associated with protection from HPV16 infection.<h4>Conclusions/significance</h4>Enrollment HPV16 seropositivity by any of the three serological assays evaluated was associated with protection from subsequent infection, although cutoffs for immune protection were different. We defined the assays and seropositivity levels after natural infection that better measure and translate to protective immunity. |
| format | Article |
| id | doaj-art-e8ac17a43a5d443080e7004b849bb09c |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-e8ac17a43a5d443080e7004b849bb09c2025-08-20T02:08:46ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0181e5306710.1371/journal.pone.0053067HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays.Shih-Wen LinArpita GhoshCarolina PorrasSarah C MarktAna Cecilia RodriguezMark SchiffmanSholom WacholderTroy J KempLigia A PintoPaula GonzalezNicolas WentzensenMark T EsserKatie MatysAriane MeureeWim QuintLeen-Jan van DoornRolando HerreroAllan HildesheimMahboobeh SafaeianCosta Rican Vaccine Trial Group<h4>Background</h4>Several serological assays have been developed to detect antibodies elicited against infections with oncogenic human papillomavirus (HPV) type 16. The association between antibody levels measured by various assays and subsequent HPV infection risk may differ. We compared HPV16-specific antibody levels previously measured by a virus-like particle (VLP)-based direct enzyme-linked immunoassay (ELISA) with levels measured by additional assays and evaluated the protection against HPV16 infection conferred at different levels of the assays.<h4>Methodology/principal findings</h4>Replicate enrollment serum aliquots from 388 unvaccinated women in the control arm of the Costa Rica HPV vaccine trial were measured for HPV16 seropositivity using three serological assays: a VLP-based direct ELISA; a VLP-based competitive Luminex immunoassay (cLIA); and a secreted alkaline phosphatase protein neutralization assay (SEAP-NA). We assessed the association of assay seropositivity and risk of subsequent HPV16 infection over four years of follow-up by calculating sampling-adjusted odds ratios (OR) and HPV16 seropositivity based on standard cutoff from the cLIA was significantly associated with protection from subsequent HPV16 infection (OR = 0.48, CI = 0.27-0.86, compared with seronegatives). Compared with seronegatives, the highest seropositive tertile antibody levels from the direct ELISA (OR = 0.53, CI = 0.28-0.90) as well as the SEAP-NA (OR = 0.20, CI = 0.06, 0.64) were also significantly associated with protection from HPV16 infection.<h4>Conclusions/significance</h4>Enrollment HPV16 seropositivity by any of the three serological assays evaluated was associated with protection from subsequent infection, although cutoffs for immune protection were different. We defined the assays and seropositivity levels after natural infection that better measure and translate to protective immunity.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0053067&type=printable |
| spellingShingle | Shih-Wen Lin Arpita Ghosh Carolina Porras Sarah C Markt Ana Cecilia Rodriguez Mark Schiffman Sholom Wacholder Troy J Kemp Ligia A Pinto Paula Gonzalez Nicolas Wentzensen Mark T Esser Katie Matys Ariane Meuree Wim Quint Leen-Jan van Doorn Rolando Herrero Allan Hildesheim Mahboobeh Safaeian Costa Rican Vaccine Trial Group HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. PLoS ONE |
| title | HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. |
| title_full | HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. |
| title_fullStr | HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. |
| title_full_unstemmed | HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. |
| title_short | HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. |
| title_sort | hpv16 seropositivity and subsequent hpv16 infection risk in a naturally infected population comparison of serological assays |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0053067&type=printable |
| work_keys_str_mv | AT shihwenlin hpv16seropositivityandsubsequenthpv16infectionriskinanaturallyinfectedpopulationcomparisonofserologicalassays AT arpitaghosh hpv16seropositivityandsubsequenthpv16infectionriskinanaturallyinfectedpopulationcomparisonofserologicalassays AT carolinaporras hpv16seropositivityandsubsequenthpv16infectionriskinanaturallyinfectedpopulationcomparisonofserologicalassays AT sarahcmarkt hpv16seropositivityandsubsequenthpv16infectionriskinanaturallyinfectedpopulationcomparisonofserologicalassays AT anaceciliarodriguez hpv16seropositivityandsubsequenthpv16infectionriskinanaturallyinfectedpopulationcomparisonofserologicalassays AT markschiffman hpv16seropositivityandsubsequenthpv16infectionriskinanaturallyinfectedpopulationcomparisonofserologicalassays AT sholomwacholder hpv16seropositivityandsubsequenthpv16infectionriskinanaturallyinfectedpopulationcomparisonofserologicalassays AT troyjkemp hpv16seropositivityandsubsequenthpv16infectionriskinanaturallyinfectedpopulationcomparisonofserologicalassays AT ligiaapinto hpv16seropositivityandsubsequenthpv16infectionriskinanaturallyinfectedpopulationcomparisonofserologicalassays AT paulagonzalez hpv16seropositivityandsubsequenthpv16infectionriskinanaturallyinfectedpopulationcomparisonofserologicalassays AT nicolaswentzensen hpv16seropositivityandsubsequenthpv16infectionriskinanaturallyinfectedpopulationcomparisonofserologicalassays AT marktesser hpv16seropositivityandsubsequenthpv16infectionriskinanaturallyinfectedpopulationcomparisonofserologicalassays AT katiematys hpv16seropositivityandsubsequenthpv16infectionriskinanaturallyinfectedpopulationcomparisonofserologicalassays AT arianemeuree hpv16seropositivityandsubsequenthpv16infectionriskinanaturallyinfectedpopulationcomparisonofserologicalassays AT wimquint hpv16seropositivityandsubsequenthpv16infectionriskinanaturallyinfectedpopulationcomparisonofserologicalassays AT leenjanvandoorn hpv16seropositivityandsubsequenthpv16infectionriskinanaturallyinfectedpopulationcomparisonofserologicalassays AT rolandoherrero hpv16seropositivityandsubsequenthpv16infectionriskinanaturallyinfectedpopulationcomparisonofserologicalassays AT allanhildesheim hpv16seropositivityandsubsequenthpv16infectionriskinanaturallyinfectedpopulationcomparisonofserologicalassays AT mahboobehsafaeian hpv16seropositivityandsubsequenthpv16infectionriskinanaturallyinfectedpopulationcomparisonofserologicalassays AT costaricanvaccinetrialgroup hpv16seropositivityandsubsequenthpv16infectionriskinanaturallyinfectedpopulationcomparisonofserologicalassays |